Human ICOSLG Stable Cell Line-CHO-K1

Name: Human ICOSLG Stable Cell Line-CHO-K1
SKU: CSC-RO0072
Availability: InStock

For research use only. Not intended for any clinical use.

Cat. No. : CSC-RO0072

Host Cell : CHO-K1 Size : >1x10⁶ frozen cells/vial

Inquire for Price

Cell Line Information

Cell Culture Information

Safety and Packaging

Gene Information

Cat. No.	CSC-RO0072
Description	This cell line is a stably transfected cell line which expresses human inducible T-cell costimulator ligand (ICOSLG).
Background	ICOSLG protein is also known as CD275. This protein is encoded by the ICOSLG gene in human.
Target	Human
Target Gene	ICOSLG
Gene Species	Homo sapiens (Human)
Host Cell	CHO-K1
Host Cell Species	Cricetulus griseus (Chinese hamster)
Source	CHO-K1
Applications	1. Studying the interactions between immune cells and cancer cells 2. Studying the mechanisms of resistance to immune checkpoint blockade 3. High-throughput screening 4. Drug target validation
Size	>1x10⁶ frozen cells/vial
Stability	Validated for at least 10 passages
Quality Control	Negative for bacteria, yeast, fungi and mycoplasma.
Storage	Liquid nitrogen
Shipping	Dry ice

Revival

Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media.

Mycoplasma	Negative
Format	One frozen vial containing millions of cells
Storage	Liquid nitrogen
Safety Considerations	The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach.
Ship	Dry ice

Gene Name	ICOSLG inducible T-cell costimulator ligand [ Homo sapiens (human) ]
Gene Symbol	ICOSLG
Synonyms	B7H2; GL50; B7-H2; B7RP1; CD275; ICOSL; LICOS; B7RP-1; ICOS-L
Gene ID	23308
Uni Prot ID	O75144
Chromosome Location	21q22.3

Quick Inquiry

Q & A

Customer Reviews

Customer Q&As

What are the specific advantages of using the Human ICOSLG Stable Cell Line-CHO for protein expression compared to other cell lines?

A: The Human ICOSLG Stable Cell Line-CHO (Chinese Hamster Ovary) offers several advantages for protein expression. Firstly, CHO cells are known for their ability to perform complex post-translational modifications, which are crucial for the proper folding and function of many therapeutic proteins. Secondly, the stable expression of ICOSLG in this cell line allows for the production of proteins with consistent glycosylation patterns, which can be critical for biopharmaceutical development. Thirdly, the Human ICOSLG Stable Cell Line-CHO may exhibit higher protein yields compared to other cell lines, which can be a significant factor in the cost-effectiveness of biomanufacturing.

How does the Human ICOSLG Stable Cell Line-CHO contribute to the development of monoclonal antibodies?

A: The Human ICOSLG Stable Cell Line-CHO can be utilized for the production of monoclonal antibodies (mAbs) with human-like glycosylation patterns. This is particularly important because the glycosylation of mAbs can significantly influence their efficacy, stability, and immunogenicity. By expressing ICOSLG, the cell line can mimic the human glycosylation machinery, leading to mAbs with improved clinical properties.

What are the challenges associated with maintaining the Human ICOSLG Stable Cell Line-CHO in long-term culture?

A: Long-term culture of the Human ICOSLG Stable Cell Line-CHO can face challenges such as genetic drift, which may lead to changes in the expression of the ICOSLG gene or other cellular characteristics. Additionally, maintaining the stability of the cell line over time requires careful monitoring and selection strategies to ensure that the desired phenotype is preserved.

What are the considerations for scaling up the production of proteins using the Human ICOSLG Stable Cell Line-CHO?

A: Scaling up protein production with the Human ICOSLG Stable Cell Line-CHO involves optimizing bioreactor conditions, such as nutrient supply, oxygen levels, and pH, to support cell growth and protein synthesis. Additionally, the process must be carefully monitored to ensure that the quality attributes of the protein, including glycosylation, remain consistent with those produced at smaller scales.

How does the Human ICOSLG Stable Cell Line-CHO support the development of personalized medicine?

A: The Human ICOSLG Stable Cell Line-CHO can be used to produce proteins with personalized glycosylation profiles, which can be tailored to individual patients' needs. This capability is particularly relevant for the development of therapeutics that require specific glycosylation patterns for optimal efficacy and safety.

What are the regulatory requirements for the use of the Human ICOSLG Stable Cell Line-CHO in clinical trials?

A: The use of the Human ICOSLG Stable Cell Line-CHO in clinical trials must comply with regulatory guidelines that ensure the safety, efficacy, and quality of the manufactured proteins. This includes demonstrating the stability of the cell line, the consistency of the protein product, and the absence of adventitious agents.

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Question *

Name

Country *

Email *

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Product Name *

Catalog Name *

Rating

Needs improvement

Satisfaction

General satisfaction

Very satisfaction

Product Review Title *

Summary *